Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted fast track designation for Pharmasset's chronic hepatitis C virus (HCV) infection treatment, PSI-938.
Subscribe to our email newsletter
PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV.
Earlier in Nuclear study , PSI-938 showed potent antiviral activity and was generally safe and well tolerated, both as monotherapy and in conjunction with the company’s lead nucleotide analog, PSI-7977.
Currently, Pharmasset intends to start Quantum combination trial with PSI-938 and PSI-7977 in the third quarter of 2011.